Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Companjen A"'
Autor:
Arjen Companjen, Joanne Goodman, Amanda Versteilen, Marianne Scheel Fjording, Ulrich Kunz, Philip Timmerman, Susanne Pihl, Karen Elsby, Timo Piironen, Ulf Loevgren, Paul Robinson
Publikováno v:
Bioanalysis. 9:1493-1508
The analysis of biomarkers by ligand-binding assays offers significant challenges compared with the bioanalysis of small and large molecule drugs. The presence of endogenous analyte is a commonly cited issue. Also the sourcing and application of appr
Autor:
Barry van der Strate, Virginia Litwin, Corinna Schoelch, Arjen Companjen, Marianne Scheel Fjording, Robin Longdin, Nora Bachmayer, Maria Cavallin, Wilfried Passe-Coutrin, Minesh Patel, Marie Geerlings
Publikováno v:
Bioanalysis. 9:1253-1264
Flow cytometry is a powerful tool that can be used for the support of (pre)clinical studies. Although various white papers are available that describe the set-up and validation of the instrumentation (the flow cytometer) and validation of flow cytome
Autor:
Martin Nemansky, Laurent Vermet, Lydia Michaut, Arjen Companjen, Ralf Loebbert, Jenny Hendriks, Susanne Pihl, Janka Ryding
Publikováno v:
Bioanalysis. 6:1409-1413
Long- and short-term stability testing of the analyte is one of the key parameters in bioanalytical method validation in support of pharmacokinetics. However, for immunogenicity testing, the scientific rationale for long- and short-term stability tes
Autor:
Peter van Amsterdam, Arjen Companjen, Stephen White, Karen Elsby, Stuart McDougall, Michaela Golob, Philip Timmerman, Margarete Brudny-Kloeppel, John Smeraglia
Publikováno v:
Bioanalysis. 6:729-732
Crystal City V meeting on Quantitative Bioanalytical Method Validation and Implementation: 2013 Revised US FDA Guidance 3–5 December 2013, Hilton Baltimore, MD, USA The meeting provided an opportunity for Industry and regulators from the US FDA to
Autor:
Philip Timmerman, Michaela Golob, Peter van Amsterdam, Silke Luedtke, Margarete Brudny-Kloeppel, Arjen Companjen
Publikováno v:
Bioanalysis. 5:645-659
The European Medicines Agency’s (EMA) 2011 guideline on bioanalytical method validation (BMV) was evaluated and subsequently intensely discussed by the European Bioanalysis Forum (EBF) during a 2-day workshop (EBF Workshop on the implementation of
Autor:
Margarete Brudny-Kloeppel, Neil Henderson, Peter van Amsterdam, Benno Ingelse, John Smeraglia, Dijksman Jessica A R, Arjen Companjen, Philip Timmerman, Hans Mulder
Publikováno v:
Bioanalysis. 4:2769-2774
One hundred and eighty scientists from industry and academia discussed the progress in emerging technologies approaching regulated bioanalysis, with a focus on what potential hurdles prevent them becoming broadly accepted by industry and regulators.
Autor:
Begona Barroso, Christian Herling, Stephanie Fischmann, Neil Henderson, Philip Timmerman, Karen Elsby, Clare Kingsley, Susanne Pihl, Birgit Jaitner, Ulrich Kunz, Amanda Versteilen, Stewart Bates, Daniela Stoellner, Arjen Companjen
Publikováno v:
Bioanalysis. 4:1883-1894
Biomarkers have become increasingly important in drug development and many bioanalysts are getting involved. Consequently, different views on how to approach the bioanalysis of biomarkers have been published or are being developed. The European Bioan
Autor:
Michaela Golob, Peter van Amsterdam, Birgitte Buur Rasmussen, Daniela Stoellner, Ben Gordon, Eva Vieser, Richard Abbott, Dijksman Jessica A R, Arjen Companjen, Philip Timmerman, Christian Herling, Begona Barroso, Margarete Brudny Kloeppel, Graeme Young, Silke Luedtke, Magnus Knutsson
Publikováno v:
Bioanalysis. 4:633-642
The 4th Open Symposium of the European Bioanalytical Forum entitled ‘Less is More’ was held on 16–18 November 2011 at the Hesperia Tower Hotel, Barcelona, Spain. More than 50 interesting presentations were delivered covering areas with interest
Autor:
Margarete Brudny-Kloeppel, Arjen Companjen, Hans Mulder, Benno Ingelse, John Smeraglia, Philip Timmerman, Neil Henderson
Publikováno v:
Bioanalysis. 5(2)
On 12–13 June 2012, the European Bioanalysis Forum hosted its third Focus Meeting in Brussels (Belgium). At the meeting, a panel discussion was held on the hurdles that the bioanalytical community encounters when adopting new technologies or managi